Milestone Pharmaceuticals Inc.

NASDAQ:MIST

Biotechnology

Healthcare
$0.46 -0.01%

-$0.00 today

Market cap
$57.32M
Beta
0.96
P/E (TTM)
-2.5
EPS (TTM)
-$0.52
52W Low $1.00High $3.06

Volume 2.23M

Average 1.99M

MIST Interest Expense

Cost of servicing the company's debt during the period.

Milestone Pharmaceuticals Inc.NASDAQ: MIST

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense growth accelerates

Q1 FY2026 interest expense of $4.14M rose 342.2% year over year, ahead of the +93.1% change in trailing-twelve-month interest expense. Sequentially, it rose 319.8% from the prior quarter.

Context

  • Interest expense amounted to 248.3% of revenue in FY2025.
  • Interest expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +342.2% holds above the trailing-twelve-month pace of +93.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.14M+319.8% QoQ
Last fiscal yearDec 2025
$3.84M+207.2% YoY
LTMMar 2026
$7.04M+93.1% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+342.2%——
1 year+207.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
3.84M USD
Year-over-year change
+207.2%

Interest Expense vs competitors

How MIST compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +93.1% is the 2nd highest of 6, against a peer median of -22.3%.
  • Interest expense amounts to 394.5% of revenue for MIST, versus a peer median of 15.8%.
MIST Competitors
Interest Expense for MIST and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$7.04M USD+93.1%—394.5%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$2.04M USD-56.5%+39.2%64.3%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$1.36M USD+128.9%-32.0%—
IPHAInnate Pharma S.A.FY2025€440K EUR-22.3%+15.2%15.8%
MOLNMolecular Partners AGLTM Mar 2026CHF 45.01K CHF+45.1%-69.7%—
PEPGPepGen Inc.LTM Mar 2026$0 USD———
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$0 USD-100.0%——
CRDFCardiff Oncology, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding MIST) —-22.3%-8.4%15.8%

Competitors are the stored peer set for MIST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue15M5M1M01.55M
Cost of Revenue0000114K
Gross Profit15M5M1M01.43M
Gross Margin100.0%100.0%100.0%—92.6%
Research & Development38.67M39.83M31.05M14.36M18.11M
Selling, General & Admin19.4M24.81M31.05M27.75M17.27M
Operating Expenses58.07M64.64M62.1M42.1M63.92M
Depreciation & Amortization93K89K92K105K114K
EBITDA(42.76M)(58.3M)(57.04M)(37.83M)(59.45M)
EBITDA Margin-285.1%-1166.0%-5703.9%—-3845.5%
Operating Income(43.07M)(59.64M)(61.1M)(42.1M)(62.49M)
Operating Margin-287.2%-1192.8%-6109.8%—-4041.7%
Interest Income220K1.25M3.97M4.16M2.92M
Interest Expense002.55M(3.58M)3.84M
Other Income / Expenses220K1.25M1.41M583K(918K)
Income Before Tax(42.85M)(58.39M)(59.69M)(41.52M)(63.4M)
Pre-Tax Margin-285.7%-1167.8%-5968.5%—-4101.1%
Income Tax Expense0000(345K)
Net Income(42.85M)(58.39M)(59.69M)(41.52M)(63.06M)
Net Margin-285.7%-1167.8%-5968.5%—-4078.8%
EPS (Basic)(1.02)(1.35)(1.39)(0.67)(0.75)
EPS (Diluted)(1.02)(1.35)(1.39)(0.67)(0.75)
Weighted Avg Shares41.83M42.45M42.96M62.21M83.88M
Weighted Avg Shares (Diluted)41.83M42.45M42.96M62.21M83.88M

Milestone Pharmaceuticals Inc.

NASDAQ:MIST

Intrinsic Alpha fair value

Locked

Current Price

$0.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.